Cogent Biosciences, Inc. (NASDAQ:COGT) shares are trading higher after the company reported initial data from its ongoing Phase 2 APEX clinical trial.
All patients treated with bezuclastinib achieved greater than or equal to 50% reduction in serum tryptase, with a median reduction of 89%, regardless of prior KIT D816V inhibitor treatment.
